Navigation Links
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Date:5/9/2013

or the first quarter of 2013 from $9.7 million year-over-year, resulting primarily from higher labor costs associated with the expansion of the Sequenom CMM sales force and increased headcount to support commercial operations.  Research and development expenses increased to $13.8 million for the first quarter of 2013, as compared to $11.8 million in the first quarter of 2012, related primarily to increased labor and supplies and costs relative to the expansion into the Sequenom CMM North Carolina facilities.

General and administrative expenses for the first quarter of 2013 were $13.5 million, as compared to $7.4 million for the first quarter of 2012, primarily due to increased legal expenses associated with patent litigation, increased collection costs due to the increase in diagnostics revenue and increased headcount to support the Company's operations.  Total stock-based compensation expense was $3.1 million for the first quarter of 2013, an increase from $2.9 million in stock-based compensation recorded for the first quarter of 2012.

Net loss for the first quarter of 2013 was $29.4 million, or $0.26 per share, as compared to net loss of $24.4 million, or $0.22 per share, for the same period in 2012.  Net cash used in operating activities was $19.7 million for the first quarter of 2013, compared to $23.3 million in the same period in the prior year.  The Company also used cash for capital investments of $4.1 million and debt repayments of $1.8 million during the first quarter of 2013.  As of March 31, 2013, total cash, cash equivalents, and marketable securities were $151.1 million.

"We are pleased to see sequential improvements in volume, revenue and margin during the quarter, an indication of steady growth and sustained momentum in 2013," said Paul V. Maier , Sequenom's CFO.  "As we complete the process of moving our billing and collections processes in-house, we anticipate even
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
2. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
3. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
4. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
7. Chindex International, Inc. Reports First Quarter 2013 Financial Results
8. BioScrip Reports First Quarter 2013 Financial Results
9. China Biologic Reports Financial Results for the First Quarter of 2013
10. Nephros Reports First Quarter 2013 Financial Results
11. PharmAthene Reports First Quarter 2013 Financial And Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... 2014 Houstonians seeking the latest information ... visit on the Internet. Paul Vitenas, JR. M.D., ... cosmetic surgeons, has launched a new website to better ... Botox Cosmetic services. The new website can ... to the new website, Botox Cosmetic is a non-surgical ...
(Date:9/30/2014)... 2014 Thanks to generous ... Children’s Oral Health Foundation: America’s ToothFairy® (NCOHF) ... non-profit clinical partners. These organizations are part ... comprehensive educational, preventive and treatment services for ...     Just Kids Dental: $25,000 America's ...
(Date:9/30/2014)... News) -- For millions of overweight Americans, regular exercise ... threat of type 2 diabetes. However, a new ... some than for others, depending on their genes. ... not be as effective for everyone when it comes ... expert, Dr. Ruth Loos, director of the Genetics of ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 The ... to reach USD 38.75 billion by 2020 at an ... to a new study by Grand View Research, Inc. ... due to lifestyle habits such as excessive alcohol consumption ... organ failure rates is expected to serve this market ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... , , WASHINGTON, July 20 ... of the people who were infected with the virus were able ... others. Recent studies have begun to unravel the cause of this ... have a unique survival advantage if they have both a low ...
... , , , BEDFORD, Mass., ... leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management ... quarter 2009 on Tuesday, August 4, 2009 after the close of ... will also host a conference call at 5:00 p.m. Eastern Time ...
... , PORTLAND, Ore. July 20 Studies ... for heart disease, stroke, and delivery of premature or low birth-weight babies. ... without dental insurance - nearly twice the rate of people without medical ... care more accessible to people, Regence Life and Health ...
... growth, metastasis, researchers say , MONDAY, July 20 (HealthDay ... may contribute to aggressive breast cancer, new research shows. ... profiles" of breast cancer tumors, researchers from the Genome ... be implicated in the development of breast cancer. , ...
... , , GREENFIELD, Wis., July ... one-of-a-kind online nutritional service and meal-planning program for cancer patients. ... www.therapeasecuisine.com . Founded by cancer survivors, the program ... registered dietitians. It is available to cancer patients and health ...
... ,The team, led by Professor Matthias Mann ... of Copenhagen and the Max Planck Institute for Biochemistry in ... "This is more than just a technological achievement, ... by a factor of six, and it gives us for ...
Cached Medicine News:Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 2Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 3Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 4Health News:Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday, August 4, 2009 2Health News:More Americans Have Cell Phones Than Dental Coverage 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:Cancer Survivors Launch New Company, TherapEase Cuisine 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: